- Exchange: NASDAQ GS
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Biotech
Dendreon Corp+ Add to Watchlist
DNDN:US0.9795 USD 0.0505 4.90%
As of 20:10:00 ET on 10/31/2014.
Company Profile for Dendreon Corp (DNDN)
Dendreon Corporation discovers and develops immunologically based therapeutic products for the treatment of cancer. The Company combines knowledge in immunology and antigen engineering with proprietary cell separation technologies to develop therapeutic vaccines that induce cell-mediated immunity, the body's key defense against cancer.
Key Executives for Dendreon Corp (DNDN)
|Douglas G Watson "Doug"Chairman||W Thomas Amick "Tom"President/CEO|
|Andrew S SandlerExec VP/Chief Medical Officer||Gregory R CoxInterim CFO/VP:Finance|
|Lindsay RoccoExec VP:Corporate Communications||William MonteithExec VP:Technical Operations|
|Bill JenkinsonVP/Chief Marketing Officer||Silvio PachecoVP/Chief Customer Officer|
|Robert CrottyVP/Interim Secy & Gen Cnsl||Karen E BrophyVP/Head:Human Resources|